New drug combination for advanced lung cancer after prior treatments
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer (NSCLC) that is advanced or cannot be surgically removed, with specific EGFR gene mutations (19del or L858R)
- Your cancer has stopped responding to at least one EGFR-targeted therapy (like erlotinib, gefitinib, or osimertinib) and to platinum-based chemotherapy
- You are between 18 and 75 years old and in good enough health to tolerate treatment (ECOG score 0 or 1)
- Your blood counts, liver, kidney, and heart function are within safe ranges for this study
- You can provide tumor tissue for testing or agree to a biopsy
- You are willing to use birth control during and for 6 months after the trial if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests a new combination of drugs for people with advanced EGFR-mutant non-small cell lung cancer whose cancer progressed after taking a third-generation EGFR-TKI drug. The combination aims to attack the cancer in two ways at once.
This trial tests a new drug (Sacituzumab Tirumotecan) combined with a third-generation EGFR pill, with or without radiation, for people with EGFR-mutant lung cancer that has spread to the brain and has stopped responding to prior targeted therapy.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.